What is Creative Med Technology Hldgs's earnings per share (EPS)?

Creative Med Technology Hldgs (CELZ) reported diluted earnings per share of -$2.52 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Creative Med Technology Hldgs Financials

CELZ

FY2025 annual

Revenue $6K -45.5% YoY

Net Income -$6.0M -9.1% YoY

EPS (Diluted) -$2.52 YoY not available

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

Creative Med Technology Hldgs (CELZ) reported $6K in revenue for fiscal year 2025, down 45.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CELZ FY2025 2026-04-24

Creative Medical Technology still operates as a development-stage company, with ongoing cash burn sustained mainly by new equity funding.

Operating cash flow of -$5.9M was close to the FY2025 net loss of -$6.0M, so the reported loss largely reflects cash leaving the business rather than noncash accounting noise. That matters because cash still rose only through financing, while shares outstanding increased 111.4% from FY2024, revealing a shareholder-funded runway rather than an internally financed model.

FY2025 revenue was only $6K while R&D spending remained $2.3M, indicating the company is still using capital to pursue development rather than to serve a real sales base. In that setup, margin percentages and even gross profit say less about the business than the size of its recurring expense base.

With total liabilities of $285K against cash of $7.2M, the balance sheet is lightly burdened by creditors even though operations consume cash heavily. The practical constraint is capital access: the company is funding research and overhead through external financing, not through working-capital turnover or debt.

Financial Health Signals

Financial health score not available

Creative Med Technology Hldgs does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Grey Zone

2.37

Creative Med Technology Hldgs scores 2.37, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($7.8M) relative to total liabilities ($285K). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Creative Med Technology Hldgs passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Creative Med Technology Hldgs reported a net loss of $6.0M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$6K

YoY-45.5%

5Y CAGR-48.4%

Creative Med Technology Hldgs generated $6K in revenue in fiscal year 2025. This represents a decrease of 45.5% from the prior year.

Net Income

-$6.0M

YoY-9.1%

Creative Med Technology Hldgs reported -$6.0M in net income in fiscal year 2025. This represents a decrease of 9.1% from the prior year.

EPS (Diluted)

-$2.52

Creative Med Technology Hldgs earned -$2.52 per diluted share (EPS) in fiscal year 2025.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$7.2M

YoY+21.3%

5Y CAGR+136.2%

10Y CAGR+206.0%

Creative Med Technology Hldgs held $7.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

Creative Med Technology Hldgs had 4M shares outstanding in fiscal year 2025.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

63.4%

YoY+3.4pp

5Y CAGR-5.8pp

Creative Med Technology Hldgs's gross margin was 63.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.4 percentage points from the prior year.

Return on Equity

-79.8%

YoY+6.9pp

Creative Med Technology Hldgs's ROE was -79.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 6.9 percentage points from the prior year.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$2.3M

YoY-5.9%

Creative Med Technology Hldgs invested $2.3M in research and development in fiscal year 2025. This represents a decrease of 5.9% from the prior year.

Share Buybacks

$10K

YoY-94.3%

Creative Med Technology Hldgs spent $10K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 94.3% from the prior year.

Capital Expenditures

Not reported for fiscal year 2025.

CELZ Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CELZ annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	N/A	$6K-45.5%	$11K+22.2%	$9K-89.8%	$89K+1.0%	$88K-46.7%	$165K-0.6%	$166K+33.0%	$124K+2491.7%	$5K	$0	$0	$0	$0	$0	$0
Cost of Revenue	N/A	$2K-50.1%	$4K+22.2%	$4K-87.4%	$28K-40.6%	$48K-5.2%	$51K+11.2%	$45K-35.3%	$70K+779.7%	$8K	$0	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	$4K-42.3%	$7K+22.2%	$5K-91.0%	$60K+51.0%	$40K-65.1%	$114K-5.1%	$120K+122.1%	$54K+1788.3%	-$3K	$0	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$2.3M-5.9%	$2.4M+21.8%	$2.0M-68.6%	$6.3M+5641.8%	$109K	$0	$0-100.0%	$97K-62.9%	$260K+204.8%	$85K	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	$3.8M+16.2%	$3.2M-9.0%	$3.6M-9.7%	$3.9M+33.0%	$3.0M+155.1%	$1.2M-5.0%	$1.2M+16.4%	$1.1M+16.9%	$899K+35.1%	$665K	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	-$6.1M-6.9%	-$5.7M-2.2%	-$5.6M+45.1%	-$10.2M-227.7%	-$3.1M-180.4%	-$1.1M+1.4%	-$1.1M-1.4%	-$1.1M	N/A	-$760K-3546.8%	-$21K	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	$0-100.0%	$4.3M+248.0%	$1.2M-35.1%	$1.9M+39.2%	$1.4M+260.6%	$378K+5801.6%	$6K	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A	N/A
Net Income	N/A	-$6.0M-9.1%	-$5.5M-3.9%	-$5.3M+47.9%	-$10.1M-152.8%	$19.2M	N/A	N/A	N/A	N/A	-$766K-2390.4%	-$31K	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$2.52	-$3.71	-$3.76	-$0.93	$5.61	-$62.69	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$0	$0	N/A	$0	$0-100.0%	$3K	N/A	$0
Cost of Revenue	$0	$0	N/A	$0	$0-100.0%	$1K	N/A	$0
Gross Profit	$0	$0	N/A	$0	$0-100.0%	$2K	N/A	$0
R&D Expenses	$459K-15.2%	$542K	N/A	$465K-7.2%	$501K-32.6%	$743K	N/A	$582K
SG&A Expenses	$1.1M+21.5%	$889K	N/A	$777K+6.2%	$732K-17.7%	$888K	N/A	$499K
Operating Income	-$1.6M-7.1%	-$1.5M	N/A	-$1.3M-0.8%	-$1.3M+23.9%	-$1.7M	N/A	-$1.1M
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$1.5M-7.6%	-$1.4M	N/A	-$1.2M-0.2%	-$1.2M+24.7%	-$1.6M	N/A	-$1.0M
EPS (Diluted)	-$0.41-7.9%	-$0.38	N/A	-$0.480.0%	-$0.48+42.2%	-$0.83	N/A	-$0.75

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

CELZ Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CELZ annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$7.8M+17.1%	$6.7M-37.8%	$10.7M-44.2%	$19.2M+70.3%	$11.3M+1469.9%	$718K+35.2%	$531K+11.2%	$477K+134.9%	$203K-37.0%	$323K+550.2%	$50K+5099.2%	$954+155.1%	$374-76.1%	$2K-49.5%	$3K
Current Assets	$7.4M+20.6%	$6.1M-40.3%	$10.3M-45.2%	$18.7M+74.6%	$10.7M+10855.0%	$98K+4.0%	$94K-70.0%	$314K+1595.6%	$18K-91.7%	$222K+347.3%	$50K+5099.2%	$954+155.1%	$374-76.1%	$2K-49.5%	$3K
Cash & Equivalents	$7.2M+21.3%	$5.9M+71.3%	$3.5M-58.3%	$8.3M-22.4%	$10.7M+10841.4%	$98K+10.6%	$89K-70.8%	$304K+2119.9%	$14K-93.8%	$222K+221768.0%	$100-89.5%	$954+155.1%	$374-52.1%	$781-29.3%	$1K
Inventory	$0-100.0%	$2K-66.7%	$7K-35.3%	$10K-6.2%	$11K	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$0-100.0%	$2K	$0-100.0%	$6K-41.7%	$10K+100.0%	$5K	$0	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$285K-13.1%	$328K-11.8%	$371K-88.8%	$3.3M+216.2%	$1.1M-97.4%	$40.5M+371.0%	$8.6M+92.4%	$4.5M+83.3%	$2.4M+407.9%	$480K+480203.0%	$100-99.9%	$154K+22.8%	$125K+26.3%	$99K+31.9%	$75K
Current Liabilities	$285K-13.1%	$328K-11.8%	$371K-88.8%	$3.3M+216.2%	$1.1M-97.4%	$40.5M+371.0%	$8.6M+92.4%	$4.5M+83.6%	$2.4M+436.5%	$454K+453764.0%	$100-99.9%	$154K+22.8%	$125K+26.3%	$99K+31.9%	$75K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$493K	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.5M+18.5%	$6.3M-38.7%	$10.3M-34.8%	$15.9M+55.3%	$10.2M+125.7%	-$39.8M-393.1%	-$8.1M-102.1%	-$4.0M-78.6%	-$2.2M-1317.2%	-$158K-418.8%	$50K+132.3%	-$153K-22.4%	-$125K-27.9%	-$98K-35.5%	-$72K
Retained Earnings	-$70.6M-9.3%	-$64.6M-9.3%	-$59.1M-9.8%	-$53.8M-23.2%	-$43.7M+29.4%	-$61.9M-142.1%	-$25.6M-49.7%	-$17.1M-398.6%	-$3.4M-346.9%	-$767K-153214.4%	-$500+99.8%	-$325K-9.4%	-$297K-10.1%	-$270K-10.5%	-$244K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$9.4M+45.6%	$6.4M-17.5%	$7.8M+33.4%	$5.9M-17.6%	$7.1M-14.9%	$8.3M+25.2%	$6.7M-3.2%	$6.9M
Current Assets	$9.0M+48.9%	$6.1M-18.1%	$7.4M+36.7%	$5.4M-18.4%	$6.6M-15.4%	$7.8M+27.9%	$6.1M-3.1%	$6.3M
Cash & Equivalents	$8.7M+52.3%	$5.7M-20.6%	$7.2M+34.1%	$5.4M-18.0%	$6.6M-14.9%	$7.7M+29.7%	$5.9M-5.1%	$6.3M
Inventory	$125K0.0%	$125K	$0-100.0%	$9940.0%	$9940.0%	$994-54.7%	$2K-35.4%	$3K
Total Liabilities	$699K+127.1%	$308K+8.0%	$285K+9.0%	$261K-5.9%	$278K-3.1%	$286K-12.6%	$328K-1.0%	$331K
Current Liabilities	$699K+127.1%	$308K+8.0%	$285K+9.0%	$261K-5.9%	$278K-3.1%	$286K-12.6%	$328K-1.0%	$331K
Total Equity	$8.7M+41.7%	$6.1M-18.7%	$7.5M+34.4%	$5.6M-18.1%	$6.8M-15.3%	$8.1M+27.1%	$6.3M-3.3%	$6.6M
Retained Earnings	-$73.5M-2.1%	-$72.0M-2.0%	-$70.6M-2.7%	-$68.7M-1.8%	-$67.5M-1.9%	-$66.2M-2.5%	-$64.6M-3.0%	-$62.7M

Not reported in any period shown, so not listed: Goodwill.

CELZ Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CELZ annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$5.9M	-$5.9M-10.5%	-$5.3M+34.0%	-$8.0M-3.0%	-$7.8M-251.9%	-$2.2M-409.9%	-$435K+64.2%	-$1.2M-15.3%	-$1.1M-18.3%	-$890K-99.8%	-$445K-2941.6%	-$15K	N/A	N/A	N/A	-$14K
Investing Cash Flow	-$226K	-$51K-100.8%	$6.3M+83.4%	$3.4M+134.2%	-$10.1M	$0+100.0%	-$250K	$0	N/A	$0+100.0%	-$10K	$0	$0	$0	$0	$0
Financing Cash Flow	$8.3M	$7.2M+393.2%	$1.5M+636.9%	-$271K-101.8%	$15.5M+20.5%	$12.8M+1750.6%	$694K-30.4%	$998K-25.7%	$1.3M+97.0%	$681K+0.7%	$677K+4770.5%	$14K	N/A	N/A	N/A	$15K
Share Buybacks	$0	$10K-94.3%	$175K-35.4%	$271K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$1.5M-11.3%	-$1.3M+31.7%	-$1.9M-65.8%	-$1.2M-0.9%	-$1.2M+27.2%	-$1.6M+18.4%	-$1.9M-97.8%	-$986K
Investing Cash Flow	$0+100.0%	-$175K-246.5%	-$51K	$0	$0	$0	$0+100.0%	-$200K
Financing Cash Flow	$4.5M+33307.1%	$13K-99.7%	$3.8M	$0	$0-100.0%	$3.4M+105.8%	$1.6M+6502.8%	-$25K
Share Buybacks	$0	$0	$0	$0	$0-100.0%	$10K	$0-100.0%	$25K

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.

CELZ Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

CELZ annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	63.4%+3.4pp	60.0%0.0pp	60.0%-7.8pp	67.8%+22.5pp	45.4%-23.9pp	69.2%-3.3pp	72.5%+29.1pp	43.4%+110.1pp	-66.7%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-102380.2%	-52216.9%	-62445.9%	-11562.5%	-3562.2%	-677.7%	-682.9%	-895.7%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-99916.8%	-49940.7%	-58739.7%	-11449.3%	21892.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-79.8%+6.9pp	-86.6%-35.5pp	-51.1%+12.8pp	-63.9%-252.0pp	188.0%	N/A	N/A	N/A	N/A	N/A	-62.1%	N/A	N/A	N/A	N/A
Return on Assets	-76.8%+5.6pp	-82.4%-33.0pp	-49.3%+3.5pp	-52.9%-223.4pp	170.5%	N/A	N/A	N/A	N/A	-237.5%-175.5pp	-62.0%	N/A	N/A	N/A	N/A
Current Ratio	25.97+7.2x	18.73-8.9x	27.66+22.0x	5.64-4.6x	10.22+10.2x	0.000.0x	0.01-0.1x	0.07+0.1x	0.01-0.5x	0.49-495.5x	496.00+496.0x	0.010.0x	0.000.0x	0.020.0x	0.04
Debt-to-Equity	0.040.0x	0.050.0x	0.04-0.2x	0.21+0.1x	0.10	N/A	N/A	N/A	N/A	N/A	0.00	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	60.0%	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	-55349.3%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	-54603.2%	N/A	N/A
Return on Equity	-17.5%+5.5pp	-23.0%	N/A	-22.1%-4.0pp	-18.1%+2.3pp	-20.3%	N/A	-15.9%
Return on Assets	-16.1%+5.7pp	-21.8%	N/A	-21.1%-3.8pp	-17.4%+2.3pp	-19.6%	N/A	-15.1%
Current Ratio	12.91-6.8x	19.69-6.3x	25.97+5.3x	20.71-3.2x	23.89-3.5x	27.39+8.7x	18.73-0.4x	19.13
Debt-to-Equity	0.080.0x	0.050.0x	0.040.0x	0.050.0x	0.040.0x	0.040.0x	0.050.0x	0.05

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Ernexa ERNA

$5.7M

In8Bio, Inc. INAB

$11.5M

Transcode Therapeutics Inc RNAZ

$2.7M

Aprea Therapeutics, Inc. APRE

$12.0M

Nls Pharmaceutics Ltd NLSP

$4.0M

Where Creative Med Technology Hldgs Ranks

Frequently Asked Questions

What is Creative Med Technology Hldgs's annual revenue?

Creative Med Technology Hldgs (CELZ) reported $6K in total revenue for fiscal year 2025. This represents a -45.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Creative Med Technology Hldgs's revenue growing?

Creative Med Technology Hldgs (CELZ) revenue declined by 45.5% year-over-year, from $11K to $6K in fiscal year 2025.

Is Creative Med Technology Hldgs profitable?

No, Creative Med Technology Hldgs (CELZ) reported a net income of -$6.0M in fiscal year 2025.

What is Creative Med Technology Hldgs's gross margin?

Creative Med Technology Hldgs (CELZ) had a gross margin of 63.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Creative Med Technology Hldgs's return on equity (ROE)?

Creative Med Technology Hldgs (CELZ) has a return on equity of -79.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Creative Med Technology Hldgs's operating cash flow?

Creative Med Technology Hldgs (CELZ) recorded an outflow of $5.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Creative Med Technology Hldgs's total assets?

Creative Med Technology Hldgs (CELZ) had $7.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Creative Med Technology Hldgs spend on research and development?

Creative Med Technology Hldgs (CELZ) invested $2.3M in research and development during fiscal year 2025.

Does Creative Med Technology Hldgs buy back shares?

Yes, Creative Med Technology Hldgs (CELZ) spent $10K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Creative Med Technology Hldgs have outstanding?

Creative Med Technology Hldgs (CELZ) had 4M shares outstanding as of fiscal year 2025.

What is Creative Med Technology Hldgs's current ratio?

Creative Med Technology Hldgs (CELZ) had a current ratio of 25.97 as of fiscal year 2025, which is generally considered healthy.

What is Creative Med Technology Hldgs's debt-to-equity ratio?

Creative Med Technology Hldgs (CELZ) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Creative Med Technology Hldgs's return on assets (ROA)?

Creative Med Technology Hldgs (CELZ) had a return on assets of -76.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Creative Med Technology Hldgs's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Creative Med Technology Hldgs (CELZ) held $7.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.9M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Creative Med Technology Hldgs's Altman Z-Score?

Creative Med Technology Hldgs (CELZ) has an Altman Z-Score of 2.37, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Creative Med Technology Hldgs's Piotroski F-Score?

Creative Med Technology Hldgs (CELZ) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Creative Med Technology Hldgs's earnings high quality?

Creative Med Technology Hldgs (CELZ) reported a net loss of $6.0M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.